Standout Papers
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (2012)
- Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. (1992)
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer (2017)
- The growing teratoma syndrome (1982)
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial (2010)
Immediate Impact
16 by Nobel laureates 16 from Science/Nature 76 standout
Citing Papers
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
2021 Standout
Works of Christopher J. Logothetis being referenced
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients
2008
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Christopher J. Logothetis | 9469 | 7820 | 6778 | 448 | 20.4k | |
| Daniel P. Petrylak | 10428 | 10847 | 4759 | 521 | 22.4k | |
| Atsushi Ochiai | 7621 | 11066 | 8819 | 586 | 24.6k | |
| Giampaolo Tortora | 7644 | 13500 | 9748 | 619 | 23.7k | |
| George Wilding | 11923 | 6748 | 9776 | 308 | 21.9k | |
| Ronald de Wit | 13147 | 10045 | 4452 | 371 | 25.7k | |
| Yoshitaka Fujii | 8943 | 8242 | 7574 | 436 | 19.6k | |
| Walter M. Stadler | 13822 | 9239 | 11753 | 466 | 26.3k | |
| David M. Nanus | 8050 | 4890 | 6088 | 326 | 14.4k | |
| Jeffrey S. Ross | 8361 | 14701 | 10115 | 673 | 27.9k | |
| David S. Hong | 6145 | 10195 | 9319 | 810 | 22.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...